9 research outputs found
Interstitial lung abnormalities in treatment-naive advanced NSCLC patients (pts): Prevalence and impact on survival.
No full textClinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.
No full textRECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
No full textFive-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
No full text
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
No full text
